Clinical Trials Logo

Filter by:
NCT ID: NCT05857982 Recruiting - Clinical trials for Relapsed/Refractory Multiple Myeloma

Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Start date: May 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A prospective, open-label, single-arm clinical study of mitoxantrone hydrochloride liposome injection combined with daratumumab and dexamethasone in the treatment of relapsed/refractory multiple myeloma

NCT ID: NCT05857917 Recruiting - Clinical trials for Renal Function Disorder

Virtual Reality for for Pain and Anxiety Distraction Strategy on Peritoneal Catheter Insertion

Start date: April 17, 2023
Phase: N/A
Study type: Interventional

This clinical trial aims to investigate the effect of VR application on reducing preoperative anxiety and the intraoperative and postoperative pain of patients who undergo peritoneal dialysis catheter insertion. The main questions it aims to answer are: 1) Whether preoperative VR application can reduce preoperative anxiety in patients undergoing peritoneal dialysis catheter insertion; 2) Whether intraoperative VR application can reduce intraoperative and postoperative pain in patients undergoing peritoneal dialysis catheter insertion; 3) Whether VR application can improve patients satisfaction of the operation. Participants will be randomly assigned to the VR group and control group, and participants in the VR group will be introduced to VR use and watch a VR video about the operating room environment 1 day before the surgery. During the procedure, participants in the VR group will watch a soothing video through the VR device. In contrast, participants in the control group will receive the usual preoperative and surgical procedures. Preoperative anxiety, intraoperative and postoperative pain, and patient satisfaction will be compared between the two arms.

NCT ID: NCT05857891 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome

Start date: May 20, 2023
Phase: N/A
Study type: Interventional

Acute respiratory distress syndrome (ARDS) is a common acute and critical disease in clinic. The clinical mortality is as high as 30%-40%. At present, there is no specific treatment. Erythropoietin (EPO), also known as erythrocyte- stimulating factor, erythropoietin, has a certain amount in normal human body, mainly synthesized by liver in infants and kidneys in adults, which can stimulate erythropoiesis. In recent years, more and more studies have shown that high-dose exogenous EPO administration has benefit effects on multi-organ protection. Therefore, we designed this prospective, double-blind, placebo-controlled trial for defecting EPO on the alveolar fluid clearance of ARDS. The study mainly answers the following questions: Does human erythropoietin accelerate the resolution of alveolar edema in ARDS? Is there any effect on hospital survival? The study will draw conclusions by comparing the control group with the experimental group.

NCT ID: NCT05857800 Recruiting - Lung Cancer Clinical Trials

Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment

NAT-LungMate
Start date: May 25, 2023
Phase:
Study type: Observational [Patient Registry]

This translational study aims to investigate how neoadjuvant therapy affects lung cancer patients by monitoring dynamic changes in the tumor environment. The study focuses on patients with histologically confirmed lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), who are eligible for neoadjuvant therapy in the LungMate clinical trial series. By analyzing intra-tumour genetic and functional heterogeneity following neoadjuvant therapy through multi-omic analysis (including genomics, transcriptomics, metabolomics and proteomics), this study could potentially identify new biomarkers or therapeutic targets that could improve lung cancer patient outcomes.

NCT ID: NCT05857332 Recruiting - Clinical trials for Locally Advanced Unresectable or Metastatic Solid Tumors

SG1906 for CLDN18.2-Positive Solid Tumors

CSG-1906-101
Start date: May 30, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients with CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.

NCT ID: NCT05856929 Recruiting - Sexual Dysfunction Clinical Trials

Sexual Dysfunction After Renal Transplantation

Start date: October 1, 2022
Phase:
Study type: Observational

A questionnaire will be send to kidney transplant recipients to investigate characteristics of them and their sexual function, all participants in the survey are anonymous and voluntary, then analyse these characteristics.

NCT ID: NCT05856864 Recruiting - Clinical trials for Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

To evaluate the efficacy Cadonilimab in combination with Ramucirumab for the treatment of advanced Hepatocellular Carcinoma that has failed at systemic therapy

NCT ID: NCT05856851 Recruiting - Clinical trials for Stroke, Acute Ischemic

Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy

PEARL
Start date: August 1, 2023
Phase: Phase 3
Study type: Interventional

A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial aiming at evaluating the efficacy and safety of intra-arterial recombinant human tissue plasminogen activator (rt-PA) after successful recanalization of acute large vessel occlusion in the anterior circulation by mechanical thrombectomy in improving the 90-day functional outcome.

NCT ID: NCT05856526 Recruiting - Netherton Syndrome Clinical Trials

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Start date: May 15, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years and older. The purpose of this study is to find out whether a medicine called spesolimab helps people with NS. Participants are divided into a spesolimab and a placebo group. Placebo injections look like spesolimab injections but do not contain any medicine. Every participant has a 2 in 3 chance of being in the spesolimab group. In the beginning, participants get the study medicine as an injection into a vein. Afterwards, they get it as an injection under the skin every month. After 4 months, participants in the placebo group switch to spesolimab treatment. Participants are in the study for about 1 year. During this time, they visit the study site 16 times. Where possible, 4 of 16 visits can be done at the participant's home instead of the study site. The doctors regularly check participants' NS symptoms. The results are compared between the groups to see whether spesolimab works. The doctors also regularly check participants' general health and take note of any unwanted effects.

NCT ID: NCT05856409 Recruiting - Ovarian Cancer Clinical Trials

Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence

Start date: May 10, 2023
Phase:
Study type: Observational

This is a prospective study to investigate the potential efficacy of 68Ga-FAPI PET/CT for recurrence detection of epithelial ovarian cancer in comparison with 18F-FDG PET/CT.